Next Article in Journal
RGB-Marking to Identify Patterns of Selection and Neutral Evolution in Human Osteosarcoma Models
Next Article in Special Issue
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma
Previous Article in Journal
Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
Previous Article in Special Issue
The Current Landscape of Clinical Trials for Systemic Treatment of HCC
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 9
10.3390/cancers13092002
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study

Cancers 2021, 13(9), 2002; https://doi.org/10.3390/cancers13092002
by Jeffrey Sum-Lung Wong 1,†, Yawen Dong 1,†, Vikki Tang 1, Thomas Leung 2, Cynthia S. Y. Yeung 3, Anna Tai 4, Ada Law 5, Tracy Shum 6, Gerry Gin-Wai Kwok 1, Bryan Cho-Wing Li 1, Roland Leung 1, Joanne Chiu 1, Ka-Wing Ma 7, Wong-Hoi She 7, Josephine Tsang 1, Tan-To Cheung 7 and Thomas Yau 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3:
Takashi Matsusaki
Cancers 2021, 13(9), 2002; https://doi.org/10.3390/cancers13092002
Submission received: 23 March 2021 / Revised: 16 April 2021 / Accepted: 17 April 2021 / Published: 21 April 2021
(This article belongs to the Special Issue Novel Therapies for Hepatocellular Carcinoma)

Round 1

Reviewer 1 Report

This a real life study well performed confirming data of the trials.

The study proposes a real life study on a drug whose clinical trial showed being efficient and well tolerated in advanced sorafenib exposed HCC patients.


The study deserves publication because it responds to the need of well organized real life study to confirm data from randomized trials. Moreover, authors describe with accuracy and details either the introduction and the discussion supporting their results. This study offers another piece of evidence among all the other anti neoplastic agents for advanced HCC as second line treatments whose need is in continuous increment trying to find the best clinical equilibrium between efficacy and tolerability. 

Author Response

Please see the attachment. 

Author Response File: Author Response.docx

Reviewer 2 Report

Cancers 1175034

 

Wong JSL. et al. analyzed the impact of the cabozantinib for the advanced HCC in Hong Kong. This manuscript has some messages to the readers of the cancers, but some refinements are needed for this manuscript.

 

1)    In the methods section, the description of the Declaration of Helsinki and IRB are necessary.

2)    In the results section, the authors should describe the precise reasons of the changing agents before administrating cabozantinib.

3)    In the fig 1., the authors should show the results of the combination patients.

Author Response

Please see the attachment. 

Author Response File: Author Response.docx

Reviewer 3 Report

They showed that the cabozantinib can achieve encouraging anti-tumour activity and survival outcomes with good tolerability in HCC patients. Their sample size was a relatively small, but this finding was quite important for severe HCC patients who didn’t have any other treatment.

I have some comments.

  1. How did you diagnose the relationship between their adverse events and cabozantinib?
  2. How did you decide single agent or combination therapy? What was this indication?

Author Response

Please see the attachment. 

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

Cancers 1175034 R1

 

The revised manuscript was corrected in accordance with the suggestions of the reviewers.

Back to TopTop